[go: up one dir, main page]

DK2819667T3 - Retinalderivater til anvendelse til forbedring af synsfunktionen - Google Patents

Retinalderivater til anvendelse til forbedring af synsfunktionen Download PDF

Info

Publication number
DK2819667T3
DK2819667T3 DK13760943.4T DK13760943T DK2819667T3 DK 2819667 T3 DK2819667 T3 DK 2819667T3 DK 13760943 T DK13760943 T DK 13760943T DK 2819667 T3 DK2819667 T3 DK 2819667T3
Authority
DK
Denmark
Prior art keywords
improve
vision function
retinal derivatives
retinal
derivatives
Prior art date
Application number
DK13760943.4T
Other languages
English (en)
Inventor
Suzanne Cadden
Original Assignee
Retinagenix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retinagenix Therapeutics Inc filed Critical Retinagenix Therapeutics Inc
Application granted granted Critical
Publication of DK2819667T3 publication Critical patent/DK2819667T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13760943.4T 2012-03-01 2013-03-01 Retinalderivater til anvendelse til forbedring af synsfunktionen DK2819667T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605729P 2012-03-01 2012-03-01
US201261642212P 2012-05-03 2012-05-03
US201261644360P 2012-05-08 2012-05-08
PCT/CA2013/050155 WO2013134867A1 (en) 2012-03-01 2013-03-01 Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Publications (1)

Publication Number Publication Date
DK2819667T3 true DK2819667T3 (da) 2020-03-30

Family

ID=49160185

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13760943.4T DK2819667T3 (da) 2012-03-01 2013-03-01 Retinalderivater til anvendelse til forbedring af synsfunktionen

Country Status (16)

Country Link
US (2) US20160296478A1 (da)
EP (1) EP2819667B8 (da)
JP (3) JP6576636B2 (da)
KR (1) KR102133608B1 (da)
CN (2) CN104470511A (da)
AU (3) AU2013232697B2 (da)
BR (1) BR112014021602A2 (da)
CA (1) CA2865935C (da)
DK (1) DK2819667T3 (da)
ES (1) ES2780357T3 (da)
IL (1) IL234306B (da)
MX (2) MX370928B (da)
NZ (1) NZ629267A (da)
PT (1) PT2819667T (da)
RU (1) RU2635536C2 (da)
WO (1) WO2013134867A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
US12029715B2 (en) * 2015-05-08 2024-07-09 University Of Debrecen Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof
EP3294711B1 (en) * 2015-05-08 2020-01-08 University of Debrecen Stereoselective synthesis of 9-cis-13,14-dihydroretinoic acid and its ethyl esters
JP7266247B6 (ja) 2016-11-17 2024-02-15 ユニバーシティー オブ デブレツェン ビタミンａ５経路のレチノイド類を提供するための前駆体化合物及びその使用
RU186184U1 (ru) * 2018-06-06 2019-01-11 Федеральное государственное бюджетное учреждение "33 Центральный научно-исследовательский испытательный институт" Министерства обороны Российской Федерации Устройство для оценки углов обзора и поля зрения испытателей в противогазе
WO2021252421A1 (en) * 2020-06-09 2021-12-16 Retinagenix Holdings Llc Methods of treating visual disorders using daily low dosing of a retinoid compound
WO2024110625A1 (en) 2022-11-24 2024-05-30 Universität Bern Cralbp based therapeutics for retinal disorders

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (da) 1973-08-21 1977-07-29 Hoffmann La Roche
US4022913A (en) 1973-09-13 1977-05-10 Hoffmann-La Roche Inc. High potency vitamin A compositions
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
CA1198859A (en) 1982-04-21 1986-01-07 Chester L. O'neal Disposable toothbrush with cap
US4532133A (en) 1983-05-24 1985-07-30 Basf Wyandotte Corporation Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
WO1995026734A1 (en) 1994-04-04 1995-10-12 Freeman William R Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
EP0839029A1 (en) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
JP4210115B2 (ja) 2001-01-11 2009-01-14 チェビジェン・インコーポレイテッド 新規レチノール誘導体および製造方法および用途
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
JP2005519878A (ja) 2001-11-30 2005-07-07 キネテク ファーマシューティカルズ，インコーポレーテッド ヒドラゾノピラゾール誘導体および治療剤としてのその使用
JP2005524626A (ja) 2002-01-18 2005-08-18 タットン テクノロジーズ エルエルシー． 眼疾患を治療するための方法
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CA2480047A1 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
JP3854524B2 (ja) 2002-04-01 2006-12-06 ピアス株式会社 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1367493A1 (en) 2002-05-30 2003-12-03 STMicroelectronics Limited Prefetch buffer
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP1610772A4 (en) 2003-03-14 2008-06-18 Univ Washington RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF
EP1510133A1 (en) 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
ES2574004T3 (es) 2003-09-04 2016-06-14 The Uab Research Foundation Procedimiento y aparato para la detección del deterioro en la adaptación a la oscuridad
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
BRPI0507807A (pt) 2004-02-17 2007-07-31 Harvard College gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular
US7919526B2 (en) 2004-03-04 2011-04-05 Htl High-Tech Lipids Ltd. Structured triglycerides and emulsions comprising same
CN1964706A (zh) 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
RU2408578C2 (ru) 2004-06-18 2011-01-10 Юниверсити Оф Вашингтон Производные ретиналя и способы их применения для лечения нарушений зрения
NZ551955A (en) 2004-06-23 2010-08-27 Revision Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20060240098A1 (en) 2004-07-14 2006-10-26 Aphios Corporation Formulations for hyperforin-enriched hypericum fractions
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) * 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
AU2006311818B9 (en) 2005-11-07 2013-05-16 Murty Pharmaceuticals, Inc Improved delivery of tetrahydrocannabinol
US8202541B2 (en) 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
AU2007277032A1 (en) 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CN101605754B (zh) 2007-01-15 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的维生素a酸类和类维生素a酸化合物的前药
US8877809B2 (en) 2007-09-12 2014-11-04 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
NZ587376A (en) 2008-02-11 2012-06-29 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction
CA2774168C (en) * 2009-09-15 2021-02-23 Ronald Erwin Boch Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
JP6340525B2 (ja) 2013-11-25 2018-06-13 株式会社デンソー モータアクチュエータ

Also Published As

Publication number Publication date
CN104470511A (zh) 2015-03-25
US10828267B2 (en) 2020-11-10
CN109248163A (zh) 2019-01-22
JP6576636B2 (ja) 2019-09-18
EP2819667A4 (en) 2015-08-05
JP2020073597A (ja) 2020-05-14
NZ629267A (en) 2016-11-25
ES2780357T3 (es) 2020-08-25
MX2014010457A (es) 2015-04-08
AU2018200415A1 (en) 2018-02-08
AU2013232697B2 (en) 2017-10-19
PT2819667T (pt) 2020-03-31
US20160296478A1 (en) 2016-10-13
AU2013232697A1 (en) 2014-09-18
JP2017197588A (ja) 2017-11-02
KR102133608B1 (ko) 2020-07-13
MX389866B (es) 2025-03-20
KR20150000881A (ko) 2015-01-05
IL234306B (en) 2022-02-01
EP2819667B1 (en) 2019-12-25
JP2015508783A (ja) 2015-03-23
EP2819667B8 (en) 2020-03-04
RU2635536C2 (ru) 2017-11-13
RU2014139666A (ru) 2016-04-20
CA2865935A1 (en) 2013-09-19
AU2019283995A1 (en) 2020-01-23
HK1205469A1 (en) 2015-12-18
US20190054039A1 (en) 2019-02-21
MX370928B (es) 2020-01-08
EP2819667A1 (en) 2015-01-07
WO2013134867A1 (en) 2013-09-19
AU2019283995B2 (en) 2021-11-11
AU2018200415B2 (en) 2019-09-26
BR112014021602A2 (pt) 2021-06-08
CA2865935C (en) 2021-12-14

Similar Documents

Publication Publication Date Title
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
BR112015006198A2 (pt) conjunto de cadeira
CO7071126A2 (es) Derivados de piridona
EP3275481C0 (en) AUTO-INJECTOR
PL3450434T3 (pl) Deuterowane pochodne ruksolitynibu
EP2838450A4 (en) STEERING ENDOLUMINAL STANZER
BR302013002886S1 (pt) Configuração aplicada à cafeteira
BR302013002882S1 (pt) Configuração aplicada à cafeteira
BR112015003160A2 (pt) corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos
BR302013002883S1 (pt) Configuração aplicada à cafeteira
DK3263564T3 (da) Aza-aryl-1h-pyrazol-1-yl-benzen-sulfonamider som ccr(9)- antagonister
DK2819667T3 (da) Retinalderivater til anvendelse til forbedring af synsfunktionen
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
BR302013002885S1 (pt) Configuração aplicada à cafeteira
EP2937730C0 (en) SPECTACLE LENSES
EP2908678A4 (en) Lighted visor
EP3040085A4 (en) Ophthalmic solution
EP2968389A4 (en) OPHTHALMIC FORMULATIONS
EP2833184A4 (en) BINOCULARS
PL2680390T3 (pl) Sposób regulowania prądu
FR2990774B1 (fr) Lentille ophtalmique
EP2851075A4 (en) PREPARATION CONTAINING A 6,7-UNSATURATED 7-CARBAMOYLMORPHINANE DERIVATIVE
ES1078038Y (es) Aposito ocular
FR2990868B1 (fr) Autoinjecteur
FR2990865B1 (fr) Autoinjecteur